Halozyme Therapeutics to present its product development pipeline

Download PDF Copy

Sep 15 2009

NewsGuard 100/100 Score

Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City. Jonathan Lim, M.D., President and CEO, is scheduled to present an overview of Halozyme and its product development pipeline on Tuesday, September 22, 2009 at 3:00 p.m. EDT (12:00 p.m. PDT).

To listen to the audio webcast of the presentation live or after the event, please visit the company’s Web site. The replay will be available for 30 days after the presentation.

http://www.halozyme.com/

Posted in: Pharmaceutical News

Tags: Biopharmaceutical, Dermatology, Drug Delivery, Endocrinology, Oncology, Pharmaceuticals, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Foam technology revolutionizes gene therapy, boosting efficiency and safety

Foam technology revolutionizes gene therapy, boosting efficiency and safety

How viral persistence and immune dysfunction drive long COVID

How viral persistence and immune dysfunction drive long COVID

New study reveals ketogenic diet's role in combating obesity

New study reveals ketogenic diet's role in combating obesity

Liraglutide activates key brain circuits to trigger weight loss in obesity

Liraglutide activates key brain circuits to trigger weight loss in obesity

Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies

Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies

How can microdialysis benefit drug development?

How can microdialysis benefit drug development?

A review of clinical features, diagnosis, and management of Mpox

A review of clinical features, diagnosis, and management of Mpox

Fungal endophytes: A promising frontier for breast cancer treatment

Fungal endophytes: A promising frontier for breast cancer treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

60 years in the making: Nanoparticles revolutionize nucleotide delivery